The effects of lintopride, a 5HT‐4 antagonist, on oesophageal motility

SUMMARY Aim: To evaluate the effects of various doses of lintopride, a new 5HT‐4 antagonist with moderate 5HT‐3 antagonist properties, on oesophageal body and lower oesophageal sphincter (LOS) motility in humans. Methods: Eight healthy male volunteers, mean age 22 (19–28) years, without any history...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Alimentary pharmacology & therapeutics 1995-10, Vol.9 (5), p.563-569
Hauptverfasser: DELVAUX, M., MAISIN, J.‐M., ARANY, Y., ATLAN, P., PRIETO‐CABANIS, M.‐J., CANAL, M., FREXINOS, J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 569
container_issue 5
container_start_page 563
container_title Alimentary pharmacology & therapeutics
container_volume 9
creator DELVAUX, M.
MAISIN, J.‐M.
ARANY, Y.
ATLAN, P.
PRIETO‐CABANIS, M.‐J.
CANAL, M.
FREXINOS, J.
description SUMMARY Aim: To evaluate the effects of various doses of lintopride, a new 5HT‐4 antagonist with moderate 5HT‐3 antagonist properties, on oesophageal body and lower oesophageal sphincter (LOS) motility in humans. Methods: Eight healthy male volunteers, mean age 22 (19–28) years, without any history of digestive disease or chest pain, were randomized to three doses of lintopride (0.1, 0.3 and 0.5 mg/kg i.v.) and a placebo at 1‐week intervals in a double‐blind, crossover study. Oesophageal motility was recorded continuously for 4 h after each dose, using perfused catheters inserted at the level of the LOS and in the body of the oesophagus, at 5, 10 and 15 cm from the LOS. Peristalsis was studied during 10 wet swallows, at 30‐min intervals (T0–T240 min). Results: The LOS basal pressure (23.3 ± 2.0 cmH2O; mean ± s.d.) remained stable after dosing with placebo to T240 After lintopride, LOS basal pressure increased significantly vs. placebo (AUC comparison: 0.1 mg/kg, P= 0.036; 0.3 mg/kg, P= 0.027; 0.5 mg/kg, P= 0.052). In contrast, the duration and extent of LOS relaxation after swallowing was not affected by any of the three doses of lintopride. The amplitude of peristaltic waves in the oesophagus increased significantly at T30 after lintopride 0.3 mg/kg (34.5 cmH2O, P= 0.020) and 0.5 mg/kg (32.5 cmH2O, P=‐0.027), at T60 after 0.3 mg/kg (48.8 cmH2O, P= 0.0009) and 0.5 mg kg (29.1 cmH2O, P= 0.029) and at T60 after 0.3 mg/kg (34.5 cmH2O, P= 0.0018). Conclusions: Lintopride significantly increased the LOS basal tone without affecting LOS physiological relaxation after swallowing. Peristaltic waves were also enhanced by lintopride.
doi_str_mv 10.1111/j.1365-2036.1995.tb00422.x
format Article
fullrecord <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_02708316v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>77776357</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3473-ac846576d2e0b5813b280b41fa50312c43d9973b18668bdfc927ea407d0a9ad53</originalsourceid><addsrcrecordid>eNqVkN2KEzEUx4Moa3f1EYQgIizsjPmYfHkhlEWtUNCLeh3OZDLbKemkTqa6vfMRfEafxAwdeu-5CeT8zsk_P4ReU1LSXO92JeVSFIxwWVJjRDnWhFSMlY9P0OLSeooWhElTME35c3Sd0o4QIhVhV-hKC02YMgu02mw99m3r3ZhwbHHo-jEehq7xdxiwWG3-_v5TYehHeIh9l8Y7HHscfYqHLTx4CHgfxy504-kFetZCSP7lfN6g758-bu5Xxfrr5y_3y3XheKV4AU5XUijZME9qkZPVTJO6oi0IwilzFW-MUbymWkpdN60zTHmoiGoIGGgEv0G3571bCDYH3cNwshE6u1qu7XSX_0U0p_InzezbM3sY4o-jT6Pdd8n5EKD38ZisyiW5UBl8fwbdEFMafHvZTImdlNudnbzayaudlNtZuX3Mw6_mV4713jeX0dlx7r-Z-5AchHaA3nXpgjFtTEWnDB_O2K8u-NN_BLDLbxshOf8HMyeb9g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77776357</pqid></control><display><type>article</type><title>The effects of lintopride, a 5HT‐4 antagonist, on oesophageal motility</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>DELVAUX, M. ; MAISIN, J.‐M. ; ARANY, Y. ; ATLAN, P. ; PRIETO‐CABANIS, M.‐J. ; CANAL, M. ; FREXINOS, J.</creator><creatorcontrib>DELVAUX, M. ; MAISIN, J.‐M. ; ARANY, Y. ; ATLAN, P. ; PRIETO‐CABANIS, M.‐J. ; CANAL, M. ; FREXINOS, J.</creatorcontrib><description>SUMMARY Aim: To evaluate the effects of various doses of lintopride, a new 5HT‐4 antagonist with moderate 5HT‐3 antagonist properties, on oesophageal body and lower oesophageal sphincter (LOS) motility in humans. Methods: Eight healthy male volunteers, mean age 22 (19–28) years, without any history of digestive disease or chest pain, were randomized to three doses of lintopride (0.1, 0.3 and 0.5 mg/kg i.v.) and a placebo at 1‐week intervals in a double‐blind, crossover study. Oesophageal motility was recorded continuously for 4 h after each dose, using perfused catheters inserted at the level of the LOS and in the body of the oesophagus, at 5, 10 and 15 cm from the LOS. Peristalsis was studied during 10 wet swallows, at 30‐min intervals (T0–T240 min). Results: The LOS basal pressure (23.3 ± 2.0 cmH2O; mean ± s.d.) remained stable after dosing with placebo to T240 After lintopride, LOS basal pressure increased significantly vs. placebo (AUC comparison: 0.1 mg/kg, P= 0.036; 0.3 mg/kg, P= 0.027; 0.5 mg/kg, P= 0.052). In contrast, the duration and extent of LOS relaxation after swallowing was not affected by any of the three doses of lintopride. The amplitude of peristaltic waves in the oesophagus increased significantly at T30 after lintopride 0.3 mg/kg (34.5 cmH2O, P= 0.020) and 0.5 mg/kg (32.5 cmH2O, P=‐0.027), at T60 after 0.3 mg/kg (48.8 cmH2O, P= 0.0009) and 0.5 mg kg (29.1 cmH2O, P= 0.029) and at T60 after 0.3 mg/kg (34.5 cmH2O, P= 0.0018). Conclusions: Lintopride significantly increased the LOS basal tone without affecting LOS physiological relaxation after swallowing. Peristaltic waves were also enhanced by lintopride.</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1111/j.1365-2036.1995.tb00422.x</identifier><identifier>PMID: 8580279</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adult ; Biological and medical sciences ; Digestive system ; Esophagogastric Junction - drug effects ; Esophagus - drug effects ; Esophagus - physiology ; Gastrointestinal Motility - drug effects ; Humans ; Imidazoles - administration &amp; dosage ; Imidazoles - pharmacology ; Life Sciences ; Male ; Medical sciences ; Muscle Contraction - drug effects ; Muscle, Smooth - drug effects ; Peristalsis - drug effects ; Pharmacology. Drug treatments ; Receptors, Serotonin - drug effects ; Receptors, Serotonin, 5-HT4 ; Reference Values</subject><ispartof>Alimentary pharmacology &amp; therapeutics, 1995-10, Vol.9 (5), p.563-569</ispartof><rights>1996 INIST-CNRS</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3473-ac846576d2e0b5813b280b41fa50312c43d9973b18668bdfc927ea407d0a9ad53</citedby><cites>FETCH-LOGICAL-c3473-ac846576d2e0b5813b280b41fa50312c43d9973b18668bdfc927ea407d0a9ad53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1365-2036.1995.tb00422.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1365-2036.1995.tb00422.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,778,782,883,1414,27911,27912,45561,45562</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2899417$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8580279$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.inrae.fr/hal-02708316$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>DELVAUX, M.</creatorcontrib><creatorcontrib>MAISIN, J.‐M.</creatorcontrib><creatorcontrib>ARANY, Y.</creatorcontrib><creatorcontrib>ATLAN, P.</creatorcontrib><creatorcontrib>PRIETO‐CABANIS, M.‐J.</creatorcontrib><creatorcontrib>CANAL, M.</creatorcontrib><creatorcontrib>FREXINOS, J.</creatorcontrib><title>The effects of lintopride, a 5HT‐4 antagonist, on oesophageal motility</title><title>Alimentary pharmacology &amp; therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>SUMMARY Aim: To evaluate the effects of various doses of lintopride, a new 5HT‐4 antagonist with moderate 5HT‐3 antagonist properties, on oesophageal body and lower oesophageal sphincter (LOS) motility in humans. Methods: Eight healthy male volunteers, mean age 22 (19–28) years, without any history of digestive disease or chest pain, were randomized to three doses of lintopride (0.1, 0.3 and 0.5 mg/kg i.v.) and a placebo at 1‐week intervals in a double‐blind, crossover study. Oesophageal motility was recorded continuously for 4 h after each dose, using perfused catheters inserted at the level of the LOS and in the body of the oesophagus, at 5, 10 and 15 cm from the LOS. Peristalsis was studied during 10 wet swallows, at 30‐min intervals (T0–T240 min). Results: The LOS basal pressure (23.3 ± 2.0 cmH2O; mean ± s.d.) remained stable after dosing with placebo to T240 After lintopride, LOS basal pressure increased significantly vs. placebo (AUC comparison: 0.1 mg/kg, P= 0.036; 0.3 mg/kg, P= 0.027; 0.5 mg/kg, P= 0.052). In contrast, the duration and extent of LOS relaxation after swallowing was not affected by any of the three doses of lintopride. The amplitude of peristaltic waves in the oesophagus increased significantly at T30 after lintopride 0.3 mg/kg (34.5 cmH2O, P= 0.020) and 0.5 mg/kg (32.5 cmH2O, P=‐0.027), at T60 after 0.3 mg/kg (48.8 cmH2O, P= 0.0009) and 0.5 mg kg (29.1 cmH2O, P= 0.029) and at T60 after 0.3 mg/kg (34.5 cmH2O, P= 0.0018). Conclusions: Lintopride significantly increased the LOS basal tone without affecting LOS physiological relaxation after swallowing. Peristaltic waves were also enhanced by lintopride.</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Digestive system</subject><subject>Esophagogastric Junction - drug effects</subject><subject>Esophagus - drug effects</subject><subject>Esophagus - physiology</subject><subject>Gastrointestinal Motility - drug effects</subject><subject>Humans</subject><subject>Imidazoles - administration &amp; dosage</subject><subject>Imidazoles - pharmacology</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Muscle Contraction - drug effects</subject><subject>Muscle, Smooth - drug effects</subject><subject>Peristalsis - drug effects</subject><subject>Pharmacology. Drug treatments</subject><subject>Receptors, Serotonin - drug effects</subject><subject>Receptors, Serotonin, 5-HT4</subject><subject>Reference Values</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkN2KEzEUx4Moa3f1EYQgIizsjPmYfHkhlEWtUNCLeh3OZDLbKemkTqa6vfMRfEafxAwdeu-5CeT8zsk_P4ReU1LSXO92JeVSFIxwWVJjRDnWhFSMlY9P0OLSeooWhElTME35c3Sd0o4QIhVhV-hKC02YMgu02mw99m3r3ZhwbHHo-jEehq7xdxiwWG3-_v5TYehHeIh9l8Y7HHscfYqHLTx4CHgfxy504-kFetZCSP7lfN6g758-bu5Xxfrr5y_3y3XheKV4AU5XUijZME9qkZPVTJO6oi0IwilzFW-MUbymWkpdN60zTHmoiGoIGGgEv0G3571bCDYH3cNwshE6u1qu7XSX_0U0p_InzezbM3sY4o-jT6Pdd8n5EKD38ZisyiW5UBl8fwbdEFMafHvZTImdlNudnbzayaudlNtZuX3Mw6_mV4713jeX0dlx7r-Z-5AchHaA3nXpgjFtTEWnDB_O2K8u-NN_BLDLbxshOf8HMyeb9g</recordid><startdate>199510</startdate><enddate>199510</enddate><creator>DELVAUX, M.</creator><creator>MAISIN, J.‐M.</creator><creator>ARANY, Y.</creator><creator>ATLAN, P.</creator><creator>PRIETO‐CABANIS, M.‐J.</creator><creator>CANAL, M.</creator><creator>FREXINOS, J.</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><general>Wiley</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope></search><sort><creationdate>199510</creationdate><title>The effects of lintopride, a 5HT‐4 antagonist, on oesophageal motility</title><author>DELVAUX, M. ; MAISIN, J.‐M. ; ARANY, Y. ; ATLAN, P. ; PRIETO‐CABANIS, M.‐J. ; CANAL, M. ; FREXINOS, J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3473-ac846576d2e0b5813b280b41fa50312c43d9973b18668bdfc927ea407d0a9ad53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Digestive system</topic><topic>Esophagogastric Junction - drug effects</topic><topic>Esophagus - drug effects</topic><topic>Esophagus - physiology</topic><topic>Gastrointestinal Motility - drug effects</topic><topic>Humans</topic><topic>Imidazoles - administration &amp; dosage</topic><topic>Imidazoles - pharmacology</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Muscle Contraction - drug effects</topic><topic>Muscle, Smooth - drug effects</topic><topic>Peristalsis - drug effects</topic><topic>Pharmacology. Drug treatments</topic><topic>Receptors, Serotonin - drug effects</topic><topic>Receptors, Serotonin, 5-HT4</topic><topic>Reference Values</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DELVAUX, M.</creatorcontrib><creatorcontrib>MAISIN, J.‐M.</creatorcontrib><creatorcontrib>ARANY, Y.</creatorcontrib><creatorcontrib>ATLAN, P.</creatorcontrib><creatorcontrib>PRIETO‐CABANIS, M.‐J.</creatorcontrib><creatorcontrib>CANAL, M.</creatorcontrib><creatorcontrib>FREXINOS, J.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Alimentary pharmacology &amp; therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DELVAUX, M.</au><au>MAISIN, J.‐M.</au><au>ARANY, Y.</au><au>ATLAN, P.</au><au>PRIETO‐CABANIS, M.‐J.</au><au>CANAL, M.</au><au>FREXINOS, J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The effects of lintopride, a 5HT‐4 antagonist, on oesophageal motility</atitle><jtitle>Alimentary pharmacology &amp; therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>1995-10</date><risdate>1995</risdate><volume>9</volume><issue>5</issue><spage>563</spage><epage>569</epage><pages>563-569</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract>SUMMARY Aim: To evaluate the effects of various doses of lintopride, a new 5HT‐4 antagonist with moderate 5HT‐3 antagonist properties, on oesophageal body and lower oesophageal sphincter (LOS) motility in humans. Methods: Eight healthy male volunteers, mean age 22 (19–28) years, without any history of digestive disease or chest pain, were randomized to three doses of lintopride (0.1, 0.3 and 0.5 mg/kg i.v.) and a placebo at 1‐week intervals in a double‐blind, crossover study. Oesophageal motility was recorded continuously for 4 h after each dose, using perfused catheters inserted at the level of the LOS and in the body of the oesophagus, at 5, 10 and 15 cm from the LOS. Peristalsis was studied during 10 wet swallows, at 30‐min intervals (T0–T240 min). Results: The LOS basal pressure (23.3 ± 2.0 cmH2O; mean ± s.d.) remained stable after dosing with placebo to T240 After lintopride, LOS basal pressure increased significantly vs. placebo (AUC comparison: 0.1 mg/kg, P= 0.036; 0.3 mg/kg, P= 0.027; 0.5 mg/kg, P= 0.052). In contrast, the duration and extent of LOS relaxation after swallowing was not affected by any of the three doses of lintopride. The amplitude of peristaltic waves in the oesophagus increased significantly at T30 after lintopride 0.3 mg/kg (34.5 cmH2O, P= 0.020) and 0.5 mg/kg (32.5 cmH2O, P=‐0.027), at T60 after 0.3 mg/kg (48.8 cmH2O, P= 0.0009) and 0.5 mg kg (29.1 cmH2O, P= 0.029) and at T60 after 0.3 mg/kg (34.5 cmH2O, P= 0.0018). Conclusions: Lintopride significantly increased the LOS basal tone without affecting LOS physiological relaxation after swallowing. Peristaltic waves were also enhanced by lintopride.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>8580279</pmid><doi>10.1111/j.1365-2036.1995.tb00422.x</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0269-2813
ispartof Alimentary pharmacology & therapeutics, 1995-10, Vol.9 (5), p.563-569
issn 0269-2813
1365-2036
language eng
recordid cdi_hal_primary_oai_HAL_hal_02708316v1
source MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects Adult
Biological and medical sciences
Digestive system
Esophagogastric Junction - drug effects
Esophagus - drug effects
Esophagus - physiology
Gastrointestinal Motility - drug effects
Humans
Imidazoles - administration & dosage
Imidazoles - pharmacology
Life Sciences
Male
Medical sciences
Muscle Contraction - drug effects
Muscle, Smooth - drug effects
Peristalsis - drug effects
Pharmacology. Drug treatments
Receptors, Serotonin - drug effects
Receptors, Serotonin, 5-HT4
Reference Values
title The effects of lintopride, a 5HT‐4 antagonist, on oesophageal motility
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T10%3A36%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20effects%20of%20lintopride,%20a%205HT%E2%80%904%20antagonist,%20on%20oesophageal%20motility&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=DELVAUX,%20M.&rft.date=1995-10&rft.volume=9&rft.issue=5&rft.spage=563&rft.epage=569&rft.pages=563-569&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1111/j.1365-2036.1995.tb00422.x&rft_dat=%3Cproquest_hal_p%3E77776357%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77776357&rft_id=info:pmid/8580279&rfr_iscdi=true